| 摘要 |
The present invention relates to a deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing the same. Specifically provided are a deuterated phenyl amino pyrimidine compound as represented by formula (I), and pharmaceutical composition containing the compound, or polymorph, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound of the present invention can treat and/or prevent JAK kinase-related diseases, such as bone marrow proliferative disease, cancer, immunologic diseases and the like. |
| 主权项 |
1. A deuterated phenyl amino pyrimidine compound of formula (I), or the crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof: wherein: R1, R2, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are each independently hydrogen or deuterium; R3, R4, R5, R6, R7, R8, R9, R10 and R11 are each independently hydrogen, deuterium, halogen, undeuterated C1-C6 alkyl or C1-C6 alkoxy, mono- or multi-deuterated or fully deuterated C1-C6 alkyl or C1-C6 alkoxy, or mono- or multi-halogenated or fully halogenated C1-C6 alkyl or C1-C6 alkoxy; R12 is selected from the group consisting of hydrogen, deuterium, halogen, OR23 COOR23, COSR23, CONHR23 and CON(R23)2; wherein R23 is selected from the group consisting of hydrogen, deuterium, substituted or and unsubstituted C1-C6 alkyl or C3-C8 cycloalkyl, wherein the substituent is selected from the group consisting of halogen, cyano, C1-C6 alkyl and C1-C6 alkoxy; with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R13, R14, R15, R16, R17, R18, R19, R20, R21 or R22 is deuterated or deuterium. |
